Page last updated: 2024-12-04

hexadecanal

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID984
CHEMBL ID1235338
CHEBI ID17600
SCHEMBL ID4481
MeSH IDM0041912

Synonyms (39)

Synonym
CHEMBL1235338
n-hexadecanal
1-hexadecanal
16-hexadecanal
CHEBI:17600 ,
ai3-24252
einecs 211-111-0
PALMITALDEHYDE ,
palmitoyl aldehyde
C00517
hexadecanal
629-80-1
palmitaldehyde, 16-hexadecanal
DB03381
palmitic aldehyde
LMFA06000088
AKOS005145523
QSPL 064
hexadecanaldehyde
H1296
palmityl aldehyde
unii-wqd27655qe
wqd27655qe ,
FT-0626966
RB3019
gtpl6627
SCHEMBL4481
n-hexadecan-1-al
hexadecylaldehyde
cetyl aldehyde
DTXSID5042039
mfcd00055568
CS-W004305
Q27077978
hexadecanal-d5
AS-56311
HY-W004305
629-80-1 (unlabeled)
SY053520

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Drug bioavailability was greatly affected as a result of microspheres formation."( In vitro evaluation of cumulative release of valproic acid and vitamin E from hexadecanol microspheres. Part 2: Antiepileptic agents.
De Caro, V; Di Stefano, V; Giannola, LI; Rizzo, MC, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
long-chain fatty aldehydeA fatty aldehyde that has a chain length ranging from C13 to C22.
2,3-saturated fatty aldehydeAny fatty aldehyde that is saturated at positions 2 and 3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (16)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Sphingolipid metabolism5550
Sphingolipid Metabolism2335
Gaucher Disease2335
Globoid Cell Leukodystrophy2335
Metachromatic Leukodystrophy (MLD)2335
Fabry Disease2335
Krabbe Disease2335
Sphingolipid metabolism (integrated pathway)1167
Sphingolipid metabolism overview415
Sphingolipid metabolism: integrated pathway163
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-20490
Sphingolipid catabolism814
sphingosine and sphingosine-1-phosphate metabolism1120
sphingolipid recycling and degradation (yeast)820
sphingolipid metabolism020
Sphingolipids metabolism pathway063
Sphingolipid metabolism415

Bioassays (2)

Assay IDTitleYearJournalArticle
AID646965Inhibition of human endothelial lipase expressed using recombinant adenovirus using glycerol-tri[9,10(n)-3H]oleate at 50 uM after 1 hr by vesicle assay2012Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
Design and synthesis of boronic acid inhibitors of endothelial lipase.
AID646966Inhibition of human lipoprotein lipase expressed using recombinant adenovirus using glycerol-tri[9,10(n)-3H]oleate at 50 uM after 1 hr by vesicle assay2012Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
Design and synthesis of boronic acid inhibitors of endothelial lipase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (38.46)18.7374
1990's2 (7.69)18.2507
2000's5 (19.23)29.6817
2010's7 (26.92)24.3611
2020's2 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 41.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index41.26 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index4.79 (4.65)
Search Engine Demand Index59.54 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (41.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]